Early diagnosis and treatment are critical to reduce the negative long-term outcomes of schizophrenia. Past research has made it easier to identify individuals who are at high risk for developing schizophrenia, but translating this knowledge into treatment requires further complex investigation. Recognizing the importance of this research, and the large scale of investment and collaboration required, the Foundation for the National Institutes of Health has launched an Accelerating Medicines Partnership on Schizophrenia.  This five-year program brings together federal, not-for-profit and private organizations dedicated to working together to advance our understanding and develop targeted interventions for high-risk populations. To learn more, see the FNIH website.